These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36548054)

  • 1. Biomimetically Engineered Amyloid-Shelled Gold Nanocomplexes for Discovering α-Synuclein Oligomer-Degrading Drugs.
    Lee D; Jung HG; Park D; Bang J; Hong JH; Lee SW; Roh S; Jang JW; Kim Y; Hwang KS; Lee YS; Park JY; Jung ID; Lee JH; Lee G; Yoon DS
    ACS Appl Mater Interfaces; 2023 Jan; 15(2):2538-2551. PubMed ID: 36548054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo.
    Colla E; Jensen PH; Pletnikova O; Troncoso JC; Glabe C; Lee MK
    J Neurosci; 2012 Mar; 32(10):3301-5. PubMed ID: 22399752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oligomer Hypothesis in α-Synucleinopathy.
    Ono K
    Neurochem Res; 2017 Dec; 42(12):3362-3371. PubMed ID: 28828740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The processes of α-synuclein amyloid protein complexes involved in the pathogenesis of Parkinson's disease].
    Kiskis J; Horvath I; Wittung-Stafshede P; Rocha S
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8):75-81. PubMed ID: 30251982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foldamers reveal and validate therapeutic targets associated with toxic α-synuclein self-assembly.
    Ahmed J; Fitch TC; Donnelly CM; Joseph JA; Ball TD; Bassil MM; Son A; Zhang C; Ledreux A; Horowitz S; Qin Y; Paredes D; Kumar S
    Nat Commun; 2022 Apr; 13(1):2273. PubMed ID: 35477706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [α-Synuclein as Diagnostic Biomarker].
    Ono K
    Brain Nerve; 2020 Feb; 72(2):137-141. PubMed ID: 32036339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruptive membrane interactions of alpha-synuclein aggregates.
    Iyer A; Claessens MMAE
    Biochim Biophys Acta Proteins Proteom; 2019 May; 1867(5):468-482. PubMed ID: 30315896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative.
    Chau E; Kim H; Shin J; Martinez A; Kim JR
    Biochem Biophys Res Commun; 2021 Oct; 574():85-90. PubMed ID: 34454326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of α-synuclein oligomers with lipid membranes.
    Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
    Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.
    Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A
    Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.
    Nors Perdersen M; Foderà V; Horvath I; van Maarschalkerweerd A; Nørgaard Toft K; Weise C; Almqvist F; Wolf-Watz M; Wittung-Stafshede P; Vestergaard B
    Sci Rep; 2015 May; 5():10422. PubMed ID: 26020724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
    Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
    Molecules; 2020 May; 25(10):. PubMed ID: 32456274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells.
    Cascella R; Chen SW; Bigi A; Camino JD; Xu CK; Dobson CM; Chiti F; Cremades N; Cecchi C
    Nat Commun; 2021 Mar; 12(1):1814. PubMed ID: 33753734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
    Ono K; Yamada M
    Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease.
    de Oliveira GAP; Silva JL
    Commun Biol; 2019; 2():374. PubMed ID: 31633065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmonic nanoparticle amyloid corona for screening Aβ oligomeric aggregate-degrading drugs.
    Lee D; Park D; Kim I; Lee SW; Lee W; Hwang KS; Lee JH; Lee G; Yoon DS
    Nat Commun; 2021 Jan; 12(1):639. PubMed ID: 33504788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying Co-Oligomer Formation by α-Synuclein.
    Iljina M; Dear AJ; Garcia GA; De S; Tosatto L; Flagmeier P; Whiten DR; Michaels TCT; Frenkel D; Dobson CM; Knowles TPJ; Klenerman D
    ACS Nano; 2018 Nov; 12(11):10855-10866. PubMed ID: 30371053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling amyloid formation paths of Parkinson's disease protein α-synuclein triggered by anionic vesicles.
    Kiskis J; Horvath I; Wittung-Stafshede P; Rocha S
    Q Rev Biophys; 2017 Jan; 50():e3. PubMed ID: 29233215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.